CoChat
Sign Up
Cited by 133Fatty Acid Research and HealthNeurotransmitter Receptor Influence on BehaviorParkinson's Disease Mechanisms and Treatments

The DOI matches its Crossref record; 293 of the 293 references it cites were found in a registry or an index.

N-3 (Omega-3) Fatty Acids: Effects on Brain Dopamine Systems and Potential Role in the Etiology and Treatment of Neuropsychiatric Disorders

Open access
Healy-Stoffel, Michelle, Levant, Beth·2018·CNS & Neurological Disorders - Drug Targets
DOI 10.2174/1871527317666180412153612PMC PMC6563911
Open this paper in CoChat — free account

Abstract

BACKGROUND & OBJECTIVE: A number of neuropsychiatric disorders, including Parkinson's disease, schizophrenia, attention deficit hyperactivity disorder, and, to some extent, depression, involve dysregulation of the brain dopamine systems. The etiology of these diseases is multifactorial, involving genetic and environmental factors. Evidence suggests that inadequate levels of n-3 (omega- 3) polyunsaturated fatty acids (PUFA) in the brain may represent a risk factor for these disorders. These fatty acids, which are derived from the diet, are a major component of neuronal membranes and are of particular importance in brain development and function. Low levels of n-3 PUFAs in the brain affect the brain dopamine systems and, when combined with appropriate genetic and other factors, increase the risk of developing these disorders and/or the severity of the disease. This article reviews the neurobiology of n-3 PUFAs and their effects on dopaminergic function. CONCLUSION: Clinical studies supporting their role in the etiologies of diseases involving the brain dopamine systems and the potential of n-3 PUFAs in the treatment of these disorders are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1871527317666180412153612

Cites

293 of 293 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 14

  1. [12]Birch EE, Garfield S, Hoffman DR, Uauy R, Birch DG. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol 2000; 42: 174– 81. 10755457
  2. [14]Galli C, Trzeciak H, Paoletti R. Effects of dietary fatty acids on the fatty acid composition of brain ethanolamine phosphoglyceride: reciprocal replacement of n-6 and n-3 polyunsaturated fatty acids. Biochim Biophys Acta 1971; 248: 449– 54.
  3. [50]Stillwell W, Shaikh SR, Zerouga M, Siddiqui R, Wassall SR. Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod Nutr Dev 2005; 45: 559– 79. 16188208
  4. [83]Aminoff MJ. Pharmacologic management of Parkinsonism & othe movement disorders In: Katzybg BG, Trevor AJ, Eds. Basic and Clinical Pharmacology. 13th ed. New York: Lange 2015; pp. 472– 89.
  5. [136]Bunney WE Jr., Bunney BG. Neurodevelopmental hypothesis of schizophrenia In: Charney DS, Neslter EJ, Bunney BS, Eds. Neurobiology of Mental Illness. Oxford: Oxford University Press 1999; pp. 225– 35.
  6. [143]Byne W, Kemether E, Jones L, Haroutunian V, Davis KL. The neurochemistry of schizophrenia In: Charney DS, Neslter EJ, Bunney BG, Eds. Neurobiology of Mental Illness. Oxford: Oxford University Press 1999; pp. 236– 45.
  7. [146]Meyer JM. Pharmacotherapy of Psychosis and Mania In: Brunton LL, B.A. C, Knollmann BC, Eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill 2011; pp. 417– 56.
  8. [193]Geyer MA, Markou A. Animal models of psychiatric disorders In: Bloom FE, Kufer DJ, Eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press 1995; pp. 787– 98.
  9. [202]Faracone SV, Biederman J. The neurobiology of attention deficit hyperactivity disorder In: Charney DS, Neslter EJ, Bunney BS, Eds. Neurobiology of Mental Illness. Oxford: Oxford University Press 1999; pp. 788– 809.
  10. [204]Szatmari P The epidemiology of attention-deficit hyperactivity disorders. Child Adolesc Psychiatr Clin North Am 1982; 1: 361– 71.
  11. [268]Nemeroff CB, Kelsey JE. Affective disorders In: Enna SJ, Coyle JT, Eds. Pharmacological Management of Neurological and Psychiatric Disorders. New York: McGraw Hill 1998; pp. 95– 136.
  12. [274]Duman RS. The neurochemistry of mood disorders: preclinical studies In: Charney DS, Nestler EJ, Eds. Neurobiology of Mental Illness. New York: Oxford University Press 2004; pp. 421– 339.
  13. [275]Garlow SJ, Musselman DL, Nemeroff CB. The neurochemistry of mood disorders: clinical studies In: Charney DS, Nestler EJ, Eds. Neurobiology of Mental Illness. New York: Oxford University Press 2004; pp. 440– 60.
  14. [281]Levant B Role of n-3 (omega-3) polyunsaturated fatty acids in postpartum depression: mechanisms and implications for prevention and treatment In: Hedge MV, A Z A, Adekar SP, Eds. Omega-3 Fatty Acids: Keys to Nutritional Health. Switzerland: Springer Science + Business Media 2016; pp. 267– 84.

Cited by

Sorted by citations

See all 133

Related

See all

Metadata

Authors
Healy-Stoffel, M., & Levant, B.
Affiliations
  • University of Wisconsin–Madison (US)
  • University of Kansas Medical Center (US)
Corresponding author
Levant, Beth
ORCID
Levant, Beth
Venue
CNS & Neurological Disorders - Drug Targets
Publisher
Bentham Science Publishers Ltd.
Published
2018-06-19
Volume
17
Issue
3
Pages
216-232
ISSN
  • 1568-007X (ISSN-L)
  • 1871-5273
DOI
10.2174/1871527317666180412153612
PMC
PMC6563911
OpenAlex
W2797781833
Cited by
133
References
293
Citations by year
2026: 12 · 2025: 19 · 2024: 21 · 2023: 11 · 2022: 18 · 2021: 20 · 2020: 19 · 2019: 10
FWCI
10.13
Type
journal article
Language
en
Open access
Locations
  • CNS & Neurological Disorders - Drug Targets (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of General Medical Sciences (P20GM103418)
  • National Institute of Neurological Disorders and Stroke (R21NS067422)
  • National Center for Research Resources (P20RR016475)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30HD002528)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
omega-3 fatty acids, omega-3 polyunsaturated fatty acids, neuropsychiatric disorders, Parkinson's disease, schizophrenia, attention deficit hyperactivity disorder, depression, dopaminergic activity, dietary fatty acids, etiology
MeSH terms
Animals, Mental Disorders, Brain, Dopamine, Humans, Fatty Acids, Omega-3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review